The Claim
Liraglutide reduces fasting and postprandial glucose levels in individuals with obesity and prediabetes within 2 weeks of treatment, independent of weight loss, and this effect is reversed by GLP-1 receptor blockade with exendin(9-39), indicating direct GLP-1R-mediated glucose regulation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Liraglutide lowers blood glucose levels after fasting and after meals in people with obesity and prediabetes within two weeks, even without weight loss, and this reduction is blocked by a specific GLP-1 receptor inhibitor, demonstrating that the effect is directly mediated by GLP-1 receptors.
See the scientific wording
Liraglutide reduces fasting and postprandial glucose levels in individuals with obesity and prediabetes within 2 weeks of treatment, independent of weight loss, and this effect is reversed by GLP-1 receptor blockade with exendin(9-39), indicating direct GLP-1R-mediated glucose regulation.
Liraglutide binds to GLP-1 receptors on pancreatic cells, which stops the liver from releasing too much sugar and makes the body’s tissues more responsive to insulin. This lowers blood sugar quickly, even before weight loss happens.
What the research says
1 studyThis study shows that a drug called liraglutide lowers blood sugar in people with obesity and prediabetes within two weeks — even before they lose weight — and when scientists blocked the drug’s target (GLP-1 receptors), the blood sugar lowering stopped. This proves the drug works directly through those receptors.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.